Cryoport (CYRX) reported $176M in revenue for fiscal 2025, +12.4% year on year. That ranks #2716 by revenue among 2853 SEC filers and #296 in Healthcare. Net income was $78.3M, a net margin of 44.4%. Revenue has grown 40.0% a year on average since 2017 ($12.0M then). The fiscal 2025 balance sheet shows $765M in total assets and $250M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $176M | +12.4% | FY20252025-12-31 |
| Gross profitGrossProfit | $83.1M | +19.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$36.8M | +$84.9M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $78.3M | +$193M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$8.6M | +$7.7M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $16.4M | −4.7% | FY20252025-12-31 |
| Total assetsAssets | $765M | +8.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $503M | +25.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $250M | +633.8% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $47.8M | −$10.5M | Open → |
| Q2 20262026-06-30 | $49.0M | −$8.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Cryoport, Inc.
- Ticker
- CYRX
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001124524
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KMar 5, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Glass House BrandsGLAS | $182M | −$29.7M |
| KamadaKMDA | $180M | $20.2M |
| Petmed ExpressPETS | $179M | −$57.3M |
| CryoportCYRX | $176M | $78.3M |
| HeartflowHTFL | $176M | −$117M |
| Phathom PharmaceuticalsPHAT | $175M | −$221,250 |
| SBC Medical GroupSBC | $174M | $51.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Cryoport — Key figures |url=https://companiesranked.com/en/company/cryoport |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Cryoport — Key figures. CompaniesRanked. https://companiesranked.com/en/company/cryoportBibTeX
@misc{companiesranked-en-company-cryoport-2026,
author = {{CompaniesRanked}},
title = {{Cryoport — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/cryoport}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-024180 · March 5, 2026
{{cite web |title=Cryoport — Key figures — 10-K (0001104659-26-024180) |url=https://www.sec.gov/Archives/edgar/data/1124524/000110465926024180/cyrx-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-05}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.